Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Experimental cancer drugs
Glesatinib
Другие языки:

    Glesatinib

    Подписчиков: 0, рейтинг: 0
    Glesatinib
    Glesatinib skeletal.svg
    Clinical data
    Routes of
    administration    		 By mouth
    ATC code
    • None
    Legal status
    Legal status
    • Investigational
    Identifiers
    • N-[(3-Fluoro-4-{[2-(5-{[(2-methoxyethyl)amino]methyl}-2-pyridinyl)thieno[3,2-b]pyridin-7-yl]oxy}phenyl)carbamothioyl]-2-(4-fluorophenyl)acetamide
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    KEGG
    Chemical and physical data
    Formula C31H27F2N5O3S2
    Molar mass 619.71 g·mol−1
    3D model (JSmol)
    • COCCNCc1ccc(nc1)c2cc3c(s2)c(ccn3)Oc4ccc(cc4F)NC(=S)NC(=O)Cc5ccc(cc5)F
    • InChI=1S/C31H27F2N5O3S2/c1-40-13-12-34-17-20-4-8-24(36-18-20)28-16-25-30(43-28)27(10-11-35-25)41-26-9-7-22(15-23(26)33)37-31(42)38-29(39)14-19-2-5-21(32)6-3-19/h2-11,15-16,18,34H,12-14,17H2,1H3,(H2,37,38,39,42)
    • Key:YRCHYHRCBXNYNU-UHFFFAOYSA-N

    Glesatinib (MGCD265) is an experimental anti-cancer drug.

    It is in phase 2 clinical trials for non-small cell lung cancer (NSCLC).

    It is a spectrum selective tyrosinekinase inhibitor "for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET".

    See also

    External links



    Новое сообщение